TISIDB

Summary
Symbol	FITM2
Name	fat storage-inducing transmembrane protein 2
Aliases	dJ881L22.2; FIT2; fat inducing transcript 2; C20orf142; chromosome 20 open reading frame 142; fat-inducing p ......
Chromosomal Location	20q13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Endoplasmic reticulum membrane Multi-pass membrane protein
Domain	PF10261 Inositol phospholipid synthesis and fat-storage-inducing TM
Function	Plays an important role in lipid droplet accumulation. Plays a role in the regulation of cell morphology and cytoskeletal organization.

> Gene Ontology [ TOP ]
Biological Process	GO:0006638 neutral lipid metabolic process GO:0006639 acylglycerol metabolic process GO:0006641 triglyceride metabolic process GO:0006644 phospholipid metabolic process GO:0008654 phospholipid biosynthetic process GO:0010866 regulation of triglyceride biosynthetic process GO:0010876 lipid localization GO:0010883 regulation of lipid storage GO:0010884 positive regulation of lipid storage GO:0010889 regulation of sequestering of triglyceride GO:0010890 positive regulation of sequestering of triglyceride GO:0019216 regulation of lipid metabolic process GO:0019432 triglyceride biosynthetic process GO:0019915 lipid storage GO:0022604 regulation of cell morphogenesis GO:0030730 sequestering of triglyceride GO:0034389 lipid particle organization GO:0035356 cellular triglyceride homeostasis GO:0045017 glycerolipid biosynthetic process GO:0046460 neutral lipid biosynthetic process GO:0046463 acylglycerol biosynthetic process GO:0046486 glycerolipid metabolic process GO:0046890 regulation of lipid biosynthetic process GO:0051235 maintenance of location GO:0055088 lipid homeostasis GO:0055090 acylglycerol homeostasis GO:0070328 triglyceride homeostasis GO:0090207 regulation of triglyceride metabolic process
Molecular Function	-
Cellular Component	GO:0030176 integral component of endoplasmic reticulum membrane GO:0031227 intrinsic component of endoplasmic reticulum membrane

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-73923: Lipid digestion, mobilization, and transport R-HSA-1430728: Metabolism R-HSA-556833: Metabolism of lipids and lipoproteins

Summary
Symbol	FITM2
Name	fat storage-inducing transmembrane protein 2
Aliases	dJ881L22.2; FIT2; fat inducing transcript 2; C20orf142; chromosome 20 open reading frame 142; fat-inducing p ......
Chromosomal Location	20q13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between FITM2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	FITM2
Name	fat storage-inducing transmembrane protein 2
Aliases	dJ881L22.2; FIT2; fat inducing transcript 2; C20orf142; chromosome 20 open reading frame 142; fat-inducing p ......
Chromosomal Location	20q13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of FITM2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	logFC: -3.33; FDR: 0.00700	Resistant to T cell-mediated killing
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	logFC: -3.03; FDR: 0.00545	Resistant to T cell-mediated killing
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	FITM2
Name	fat storage-inducing transmembrane protein 2
Aliases	dJ881L22.2; FIT2; fat inducing transcript 2; C20orf142; chromosome 20 open reading frame 142; fat-inducing p ......
Chromosomal Location	20q13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of FITM2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.333	0.192
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.71	0.61
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.057	0.957
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.327	0.225
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.393	0.743
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.244	0.868
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.12	0.67
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.022	0.976
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.29	0.697
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.508	0.637
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.099	0.946
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.137	0.0987

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of FITM2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	FITM2
Name	fat storage-inducing transmembrane protein 2
Aliases	dJ881L22.2; FIT2; fat inducing transcript 2; C20orf142; chromosome 20 open reading frame 142; fat-inducing p ......
Chromosomal Location	20q13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FITM2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	FITM2
Name	fat storage-inducing transmembrane protein 2
Aliases	dJ881L22.2; FIT2; fat inducing transcript 2; C20orf142; chromosome 20 open reading frame 142; fat-inducing p ......
Chromosomal Location	20q13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FITM2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FITM2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	FITM2
Name	fat storage-inducing transmembrane protein 2
Aliases	dJ881L22.2; FIT2; fat inducing transcript 2; C20orf142; chromosome 20 open reading frame 142; fat-inducing p ......
Chromosomal Location	20q13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FITM2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	FITM2
Name	fat storage-inducing transmembrane protein 2
Aliases	dJ881L22.2; FIT2; fat inducing transcript 2; C20orf142; chromosome 20 open reading frame 142; fat-inducing p ......
Chromosomal Location	20q13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of FITM2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	FITM2
Name	fat storage-inducing transmembrane protein 2
Aliases	dJ881L22.2; FIT2; fat inducing transcript 2; C20orf142; chromosome 20 open reading frame 142; fat-inducing p ......
Chromosomal Location	20q13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between FITM2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	FITM2
Name	fat storage-inducing transmembrane protein 2
Aliases	dJ881L22.2; FIT2; fat inducing transcript 2; C20orf142; chromosome 20 open reading frame 142; fat-inducing p ......
Chromosomal Location	20q13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting FITM2 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse FITM2